Graphite Bio Announces Participation in Upcoming Investor Conferences
January 27 2022 - 8:00AM
Business Wire
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,
next-generation gene editing company focused on therapies that
harness targeted gene integration to treat or cure serious
diseases, today announced participation in the following upcoming
investor conferences:
- Cowen 2nd Annual Genetic Medicines Summit: Josh Lehrer,
M.D., chief executive officer of Graphite Bio, will be a featured
speaker on the “Clinical Development Topics: Gene Editing” panel on
Thursday, Feb. 3, 2022, at 11 a.m. ET.
- 11th Annual SVB Leerink Global Healthcare Conference:
Fireside chat on Thursday, Feb. 17, 2022, at 1:40 p.m. ET.
The fireside chat will be webcast live from Graphite Bio’s
website at www.graphitebio.com in the Investors section. A replay
of the webcast will be archived and available following the
event.
About Graphite Bio Graphite Bio is a clinical-stage,
next-generation gene editing company harnessing high efficiency
targeted gene integration to develop a new class of therapies to
potentially cure a wide range of serious and life-threatening
diseases. Graphite Bio is pioneering a precision gene editing
approach that could enable a variety of applications to transform
human health through its potential to achieve one of medicine’s
most elusive goals: to precisely “find & replace” any gene in
the genome. Graphite Bio’s platform allows it to precisely correct
mutations, replace entire disease-causing genes with normal genes
or insert new genes into predetermined, safe locations. The company
was co-founded by academic pioneers in the fields of gene editing
and gene therapy, including Maria Grazia Roncarolo, M.D., and
Matthew Porteus, M.D., Ph.D.
Learn more about Graphite Bio by visiting www.graphitebio.com
and following the company on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220127005171/en/
Company: Stephanie Yao VP, Communications and Investor
Relations 443-739-1423 syao@graphitebio.com
Investor Relations: Stephanie Ascher Stern IR, Inc.
212-362-1200 ir@graphitebio.com
Media: Joey Fleury Real Chemistry 415-946-1090
media@graphitebio.com
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From May 2024 to Jun 2024
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jun 2023 to Jun 2024